How Dapagliflozin may improve kidney function and heart health in kidney transplant patients

Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients

NIH-funded research University of Colorado Denver · NIH-11001552

This study is looking at how the diabetes medication Dapagliflozin can help improve kidney function and heart health in people who have had kidney transplants, with the hope of reducing serious health issues like heart disease.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Colorado Denver NIH-funded
Lab location1 site (Aurora, UNITED STATES)
Project IDNIH-11001552 on NIH RePORTER

What this research studies

This research investigates the effects of Dapagliflozin, a medication typically used for diabetes, on kidney function and cardiovascular health in individuals who have received kidney transplants. The study aims to understand how this medication can help mitigate complications such as cardiovascular disease, which is a leading cause of death in kidney transplant recipients. By analyzing kidney biopsies and using advanced techniques like single-cell RNA sequencing, researchers will explore the underlying mechanisms that may enhance kidney health and oxygenation. Participants may receive Dapagliflozin as part of their treatment regimen to assess its benefits over time.

Who could benefit from this research

Good fit: Ideal candidates for this research are adults aged 21 and older who have received a kidney transplant and may have diabetes or are at risk for cardiovascular disease.

Not a fit: Patients who have not undergone kidney transplantation or those without any risk factors for cardiovascular disease may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved kidney function and reduced cardiovascular risks for kidney transplant recipients.

How similar studies have performed: Previous studies have shown that medications like Dapagliflozin can improve outcomes in patients with chronic kidney disease, suggesting a promising avenue for kidney transplant recipients as well.

Where this research is happening

Aurora, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions acute kidney injuryadult onset diabetesAdult-Onset Diabetes Mellitus
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.